Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Extensive Stage Small Cell Lung Cancer
NCT06095505Phase 2Recruiting
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Feb 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alisertib in small cell lung cancer (SCLC), sponsored by Puma Biotechnology, Inc. Primary endpoints: Objective Response Rate up to 36 months, Duration of Response up to 36 months and 3 more. Started Feb 2024; status: recruiting.
02
Drugs
alisertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06095505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095505.